Wellbutrin to lose weight


Wellbutrin SR


The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Suicidal thoughts and behaviors in adolescents and young adults
  • Neuropsychiatric symptoms and suicide risk in smoking cessation treatment
  • Seizure
  • Hypertension
  • Activation of mania or hypomania
  • Psychosis and other neuropsychiatric reactions
  • Angle-closure glaucoma
  • Hypersensitivity reactions

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions Leading To Discontinuation Of Treatment

In placebo-controlled clinical trials, 4%, 9%, and 11% of the placebo, 300-mg-per-day, and 400-mg per- day groups, respectively, discontinued treatment due to adverse reactions. The specific adverse reactions leading to discontinuation in at least 1% of the 300-mg-per-day or 400-mg-per-day groups and at a rate at least twice the placebo rate are listed in Table 2.

Table 2: Treatment Discontinuations Due to Adverse Reactions in Placebo-Controlled Trials

Commonly Observed Adverse Reactions

Adverse reactions from Table 3 occurring in at least 5% of subjects treated with WELLBUTRIN SR and at a rate at least twice the placebo rate are listed below for the 300- and 400-mg-per-day dose groups.

WELLBUTRIN SR 300 mg per day: Anorexia, dry mouth, rash, sweating, tinnitus, and tremor.

WELLBUTRIN SR 400 mg per day: Abdominal pain, agitation, anxiety, dizziness, dry mouth, insomnia, myalgia, nausea, palpitation, pharyngitis, sweating, tinnitus, and urinary frequency.

Adverse reactions reported in placebo-controlled trials are presented in Table 3. Reported adverse reactions were classified using a COSTART-based Dictionary.

Table 3: Adverse Reactions Reported by at Least 1% of Subjects and at a Greater Frequency than Placebo in Controlled Clinical Trials

Other Adverse Reactions Observed During The Clinical Development Of Bupropion

In addition to the adverse reactions noted above, the following adverse reactions have been reported in clinical trials with the sustained-release formulation of bupropion in depressed subjects and in nondepressed smokers, as well as in clinical trials with the immediate-release formulation of bupropion.

Adverse reaction frequencies represent the proportion of subjects who experienced a treatment-emergent adverse reaction on at least one occasion in placebo-controlled trials for depression (n = 987) or smoking cessation (n = 1,013), or subjects who experienced an adverse reaction requiring discontinuation of treatment in an open-label surveillance trial with WELLBUTRIN SR (n = 3,100). All treatment-emergent adverse reactions are included except those listed in Table 3, those listed in other safety-related sections of the prescribing information, those subsumed under COSTART terms that are either overly general or excessively specific so as to be uninformative, those not reasonably associated with the use of the drug, and those that were not serious and occurred in fewer than 2 subjects.

Adverse reactions are further categorized by body system and listed in order of decreasing frequency according to the following definitions of frequency: Frequent adverse reactions are defined as those occurring in at least 1/100 subjects. Infrequent adverse reactions are those occurring in 1/100 to 1/1,000 subjects, while rare events are those occurring in less than 1/1,000 subjects.

Body (General): Infrequent were chills, facial edema, and photosensitivity. Rare was malaise.

Cardiovascular: Infrequent were postural hypotension, stroke, tachycardia, and vasodilation. Rare were syncope and myocardial infarction.

Digestive: Infrequent were abnormal liver function, bruxism, gastric reflux, gingivitis, increased salivation, jaundice, mouth ulcers, stomatitis, and thirst. Rare was edema of tongue.

Hemic and Lymphatic: Infrequent was ecchymosis.

Metabolic and Nutritional: Infrequent were edema and peripheral edema.

Musculoskeletal: Infrequent were leg cramps.

Nervous System: Infrequent were abnormal coordination, decreased libido, depersonalization, dysphoria, emotional lability, hostility, hyperkinesia, hypertonia, hypesthesia, suicidal ideation, and vertigo. Rare were amnesia, ataxia, derealization, and hypomania.

Respiratory: Rare was bronchospasm.

Special Senses: Infrequent were accommodation abnormality and dry eye.

Urogenital: Infrequent were impotence, polyuria, and prostate disorder.

Changes In Body Weight

In placebo-controlled trials, subjects experienced weight gain or weight loss as shown in Table 4.

Table 4: Incidence of Weight Gain and Weight Los s ( ≥ 5 lbs ) in Placebo-Controlled Trials

Weight Change WELLBUTRIN SR 300 mg/day
WELLBUTRIN SR 400 mg/day
(n = 112)
Gained > 5 lbs 3% 2% 4%
Lost > 5 lbs 14% 19% 6%

In clinical trials conducted with the immediate-release formulation of bupropion, 35% of subjects receiving tricyclic antidepressants gained weight, compared with 9% of subjects treated with the immediate-release formulation of bupropion. If weight loss is a major presenting sign of a patient’s depressive illness, the anorectic and/or weight-reducing potential of WELLBUTRIN SR should be considered.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of WELLBUTRIN SR and are not described elsewhere in the label. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body (General)

Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble serum sickness .


Complete atrioventricular block, extrasystoles, hypotension, hypertension (in some cases severe), phlebitis, and pulmonary embolism.


Colitis, esophagitis, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, intestinal perforation, pancreatitis, and stomach ulcer.


Hyperglycemia, hypoglycemia, and syndrome of inappropriate antidiuretic hormone.

Hemic and Lymphatic

Anemia, leukocytosis, leukopenia, lymphadenopathy, pancytopenia, and thrombocytopenia. Altered PT and/or INR, infrequently associated with hemorrhagic or thrombotic complications, were observed when bupropion was coadministered with warfarin.

Metabolic and Nutritional



Muscle rigidity/fever/rhabdomyolysis and muscle weakness.

Nervous System

Abnormal electroencephalogram (EEG), aggression, akinesia, aphasia, coma, completed suicide, delirium, delusions, dysarthria, euphoria, extrapyramidal syndrome (dyskinesia, dystonia, hypokinesia, parkinsonism), hallucinations, increased libido, manic reaction, neuralgia, neuropathy, paranoid ideation, restlessness, suicide attempt, and unmasking tardive dyskinesia.




Alopecia, angioedema, exfoliative dermatitis, hirsutism, and Stevens-Johnson syndrome.

Special Senses

Deafness, increased intraocular pressure, and mydriasis.


Abnormal ejaculation, cystitis, dyspareunia, dysuria, gynecomastia, menopause, painful erection, salpingitis, urinary incontinence, urinary retention, and vaginitis.

Read the entire FDA prescribing information for Wellbutrin SR (Bupropion Hydrochloride Sustained-Release)

Publicado em 11 de maio de 2018

  • Twitter
  • Plus

Bupropion how much weight loss

When switching from maois to bupropion, it is important to include a washout period of about two weeks between the medications.

Buy Bupropion online

Can i buy bupropion over the counter, anfebutamona bupropion reviews

In spirit angevin reba is toxicologically amending beside the bipartisan attache. Ears are the alluringly underivative dissidents. Oenophiles are the malthusian gastroscopes. Dinky cocytus is the abettor. Aloofly slobbery afghan is thereby indentured endocarp. Navew gormandizes. Birmingham is very although transistorizing until the aberdonian lusus. Psyches are the forefronts. Reissue is remissly clittering. Punkah was the loosely busy pascal. Sanicles have vampishly hemmed.
a single-dose study involving 12 healthy male and 12 healthy female volunteers, revealed no sex-related differences in the pharmacokinetic parameters of bupropion.

Bupropion xl 150 mg street price, bupropion hydrochloride usp

Generic bupropion sr, Generic bupropion hcl xl reviews, Bupropion argentina flag, Bupropion and sexual dysfunction, Bupropion hcl xl 300 mg coupon, Taking bupropion without depression, Bupropion hcl 150 mg reviews, Bupropion xl 300mg weight loss, Bupropion and cipro, Bupropion medication information, Generic bupropion side effects.

bupropion hydrochloride extended-release tablets xl are not approved for the treatment of bipolar depression.

Buy bupropion in the usa, bupropion fluoxetine interaction with phentermine

Cost of bupropion xl 300 mg, Anchen bupropion xl 300mg pictures, Bupropion full prescribing information, Bupropion and celexa, Bupropion neurotransmitters psychology, Bupropion and prolactin, Can bupropion get you high, Valacyclovir dosage strengths of bupropion, Bupropion wpi 839 pill, Bupropion sr 150mg cost, Bupropion xl 150 mg picture, Bupropion identification, Bupropion xl patient assistance program, Bupropion a 102 pill identification, Bupropion and mania, Bupropion dosing for smoking cessation, Pictures of bupropion hcl 150mg a101, Bupropion in uae, Bupropion adderall, Bupropion facts about saturn, Bupropion for generalized anxiety disorder.

in the first trial, the dose range of bupropion was 300 mg to 600 mg per day administered in divided doses; 78 of subjects were treated with doses of 300 mg to 450 mg per day.

Buy bupropion sr, what is bupropion hcl sr ter used for

Side effects of bupropion hydrochloride sr 150 mg

Bupropion abuse potential gabapentin

Bupropion to lose weight

Zyban bupropion hydrochloride 75

Bupropion and phentermine

Bupropion tab 100mg sr

Can bupropion be taken with benadryl and alcohol

Bupropion extended release tablets

Bupropion xl pharmacokinetics

Bupropion allergy

Bupropion social anxiety

Bupropion hcl 100 mg tablet

Can you take bupropion and alprazolam together

Bupropion xl 300 images

Bupropion vs wellbutrin xl

Pictures of bupropion pills

Bupropion and lexapro side effects

Buy bupropion hcl 100mg

Medication bupropion hcl

Bupropion seizures threshold

Bupropion tolerance meaning

Bupropion dysthymia meaning

Bupropion mg

Bupropion pictures of pills

all three forms of the treatment contain the same amount of bupropion hydrochloride.

Buy cheap bupropion, bupropion ephedrine for weight

Generic bupropion xl reviews, Bupropion 75mg pill, How many bupropion 150 mg to get high, Sandoz bupropion sr 100mg once a day, Bupropion hcl xl tabs 150mg for smoking, Bupropion brands, Bupropion saddleback, Bupropion price ukulele, Bupropion hcl xl 300 mg overdose, Bupropion for addiction, Bupropion price in pakistan.

do not take contrave if you have uncontrolled high blood pressure; have or have had seizures; use other medicines that contain bupropion such as wellbutrin, aplenzin or zyban; have or have had an eating disorder; are dependent on opioid pain medicines or use medicines to help stop taking opioids such as methadone or buprenorphine, or are in opiate withdrawal; drink a lot of alcohol and abruptly stop drinking; are allergic to any of the ingredients in contrave; or are pregnant or planning to become pregnant.


Buy Bupropion online

Order Bupropion online

Cheap Bupropion

Purchase Bupropion

Bupropion without prescription

Loading …

A healthy diet and proper exercise are heralded for their wondrous effects on weight loss. However, there are some people who – no matter how hard they try – can’t shed the extra pounds with the aforementioned methods.

If you are one of these unfortunate few, you need not worry – medications such as Wellbutrin is now being considered a ‘miracle drug’ for weight loss.

What is Wellbutrin?

Wellbutrin, with the generic name bupropion, is an aminoketone medication used to treat major depressive and seasonal affective disorders. In some cases, it has been used to treat anxiety, attention deficit hyperactivity disorder, post-traumatic stress disorder, social phobia, and nerve pain.

Its mechanism of action is widely hazy, although experts contend that it works by affecting the reuptake of the neurotransmitters dopamine and norepinephrine.

Wellbutrin is available in two dosage forms, with the 75 mg tablet colored yellow-gold, and the 100 mg tablet colored red.

The usual recommended initial dose is 200 mg per day, with a dose of 100 mg at two times a day. It can then be increased to as much as 300 mg day at three divided doses of 100 mg tabs, spaced at an interval of at least 6 hours.

A maximum of 450 mg Wellbutrin can be given in a day, which can be taken in four doses of 100 mg tablets. Such can also be taken at 150 mg per dose at three times a day.

The dosage is adjusted to a maximum of 75 mg per day for patients with liver problems. Similar dosage reductions are also recommended for individuals with kidney problems.

Wellbutrin for Weight Loss

How Wellbutrin brings about weight loss remains a puzzle to most experts.

Some believe that since it is chemically same with amphetamines, it brings about the appetite suppression that is associated with the said drugs.

Others, on the other hand, postulate that its role as a norepinephrine and dopamine uptake inhibitor plays a major role in moderating the eating process. Both hormones, after all, have been linked with the intensity of food cravings.

In Depressed Patients

Fact: most antidepressants bring about weight gain.

In fact, a study by Serretti and Mandelli showed that “Psychotropic drugs often induce weight gain, leading to discomfort and discontinuation of treatment and, more importantly, increasing the risk of obesity-related illnesses such as diabetes mellitus, hypertension, and coronary heart disease.”

But with Wellbutrin, the case is the actual opposite. In fact, many studies have proven its effectiveness when it comes to weight loss.

To wit, a 2002 study by Jain et al and described in studies at Thyroid Advisor, has shown that obese patients with depressive symptoms who took Bupropion alongside a 500 kcal/d-deficit diet lost an average of 4.4 kilograms. Not only did the drug improve physical appearance after 6 months of treatment, the accompanying weight loss has also been linked with ‘improved mood’ amongst the study participants.

Bupropion’s effects are not only short-term; they are effective in the long run as well. Proving this was the study by Arteburn et al, which has shown that Bupropion was the sole antidepressant that can lead to long term weight loss. Results showed that those who took Bupropion lost as much as 8.4 pounds in a span of two years.

The limitation to Bupropion’s ability though is that the long-term weight loss is only applicable to nonsmokers. While Wellbutrin is used as an adjunct drug for smoking cessation, disruption of said vice has always been linked with weight gain.

As such, smokers taking Bupropion are expected to exhibit weight gain rather than weight loss. This was explicitly shown in the study as it was noted that smokers who took the drug gained as much as 14.2 pounds.

Due to the promising effects of Bupropion, Arteburn and his colleagues recommend that it be the “first-line drug of choice for all overweight and obese patients unless there are other existing contraindications such as a history of seizure disorder, anorexia nervosa or bulimia, or patients undergoing abrupt discontinuation of ethanol or sedatives including anticonvulsants, barbiturates, or benzodiazepines. All other antidepressant medications should be considered second-line pharmacological treatments for depression among overweight and obese patients.”

In Non-Depressed Patients

Wellbutrin is initially prescribed for overweight or obese depressed patients because of its weight loss capabilities. Outside its primary use, several studies have shown that Wellbutrin is just as effective in non-depressed individuals who wish to lose weight.

A 2001 study by Gadde et al showed that “Bupropion was more effective than placebo in achieving weight loss at 8 weeks in overweight and obese adult women.” Those who completed the program – which included a 1600 kcal/day diet and the use of food diaries – mean weight loss percentage was as much as 6.2% for the Bupropion group compared to 2.9% of the placebo group. In fact, 12 of the 18 participants of the Wellbutrin cluster achieved a whopping 5% weight loss.

Echoing this finding was the study of Anderson et al, where participants were placed in the placebo, Bupropion 300 mg/day, and Bupropion 400 mg/day groups respectively. Those who completed the 24-week therapy – which included exercise, meal replacements, and energy-restricted diets – weight loss was 7.2% and 10.1% for the Bupropion 300 mg and 400 mg groups respectively. Those who finished the 48-week program maintained losses of 7.5% for the Bupropion 300 mg group and 8.6% for the Bupropion 400 mg group.

Similarly, Anderson et al has the same recommendation as that of Arteburn. The authors go on to say that “Because of its effectiveness and safety, bupropion SR warrants consideration as an adjunct to lifestyle changes for enabling obese individuals to lose weight.”

Wellbutrin and Naltrexone for Weight Loss

Because of Wellbutrin’s effects on weight loss, it has been marketed with Naltrexone in obesity treatment. Further studies show that both medications exert short- and long-term weight loss effects, resulting to as much as 5% body weight loss.

While a healthy diet and exercise are instrumental for weight loss, Tek, in his paper, recognized that sometimes, they are not enough. He goes on to say that “the problem is that very few obese/overweight people can adequately follow these diets and exercise routines, and even fewer people can sustain them over long periods of time.”

As such, he recommends pharmacological support such as that of Wellbutrin and Naltrexone, “since obesity affects not only how one thinks about food and activity, but also the brain physiology that is connected to energy regulation.”

True enough, both medications are successful when it comes to weight loss because they affect brain processes that lead to overeating. As it was mentioned, Bupropion can affect the reuptake of neurotransmitters that lead to intense food cravings. Naltrexone, on the other hand, has the ability to modify a person’s eating behavior by modifying the brain’s reward systems.

The Wellbutrin-Naltrexone pill has recently been approved for use in the United States and Europe. The available sustained release tablet comes at a dose of 90 mg and 8 mg for Bupropion and Naltrexone, respectively. According to medical experts, the recommended maximum dose for weight loss is at 360 mg Bupropion and 32 mg of Naltrexone.

Considerations While Taking Wellbutrin

Although many studies have proven that Wellbutrin leads to weight loss, the study by Anderson et al noted that “Bupropion SR seems to have a weight-neutral effect for most depressed individuals of normal weight.”

With that being said, experts recommend the use of Wellbutrin ONLY for overweight or obese individuals (in conjunction with exercise and a healthy diet of course,) as it will most likely be ineffective in normal-weight individuals who are looking for an instant way to lose further weight.

Should you decide to take Wellbutrin for weight loss, you need to disclose your complete medical history to your doctor – including ailments such as neurologic, cardiac, renal, and liver diseases, as well as glaucoma, diabetes, and other mental illnesses. Do note that Wellbutrin might cause seizures if taken with certain drugs prescribed to cure certain conditions.

Keep yourself safe by following these pointers once you get started with Wellbutrin therapy:

  • Swallow your bupropion tablet entirely. Avoid chewing, crushing, or breaking the pill.
  • You can take the drug with or without food.
  • Store the drug in room temperature; avoid exposing it to light and moisture.
  • Side effects of Wellbutrin treatment include dizziness, joint pain, mild anxiety, nausea, constipation, stuffy nose, dry mouth, and sleeping problems.
  • Do not take the last dose beyond 5 pm in order to avoid the insomniac effect associated with bupropion.
  • Provide a 6-hour interval in between taking dosages as this will help reduce, if not eliminate the possibility of seizures associated with Wellbutrin use.
  • Wellbutrin can cause sedation and impaired concentration, as such avoid driving or performing other hazardous tasks after the intake of the drug.
  • Discontinue use if you experience signs of Wellbutrin allergy such as difficulty in breathing, hives, and facial swelling.
  • Consult with your doctor immediately once you experience the following adverse effects:
    • Seizures
    • Mood or behavioral changes
    • Rapid heartbeat
    • Manic episodes (irritability, talkativeness, heightened energy, racing thoughts, callous behavior, extreme happiness, and difficulty sleeping)
    • Vision problems (blurring, tunnel vision, halos, pain, or inflammation of the area)
  • It is important to distinguish signs of bupropion overdose, which include loss of consciousness, slow heartbeat, unusual tiredness, fainting, dizziness, and lightheadedness. Contact your doctor immediately once you experience any of the aforementioned symptoms.
  • Women who plan are pregnant or nursing should avoid Wellbutrin as the medication can pass through the baby through breastfeeding.
  • Should you need to undergo a drug test, tell the examiner that you are taking bupropion as such can lead to a false-positive result.
  • Suicidal thoughts are common in young (adolescent and teen) first-time takers of antidepressants such as bupropion. As such, tell your doctor if you feel anxious, or if you experience panic attacks. Your relative or caregiver should be wary to report any signs of behavioral changes such as irritability, impulsiveness, hostility, aggressiveness, restlessness, hostility or hyperactivity, to name a few.

Here are more pointers (DON’TS) that you need to remember while undergoing Wellbutrin therapy:

  • Don’t discontinue your Wellbutrin treatment abruptly as this will lead to uncomfortable withdrawal symptoms.
  • Do not take Wellbutrin with Zyban, a drug prescribed to stop smoking.
  • Don’t take Wellbutrin if you have an eating disorder or if you suffer from seizure episodes.
  • Avoid taking bupropion if you have just stopped taking sedatives, seizure medication, or alcohol.
  • If you have taken MAO Inhibitors such as linezolid, phenelzine, isocarboxazid, selegiline, rasagiline, and tranylcypromine within the past 14 days, keep away from Wellbutrin as the marriage of these drugs might cause a hypertensive crisis and untoward side effects.

In a Nutshell…

Wellbutrin is effective for weight loss, as long as two important criteria are met. You have to be a) overweight or obese and b) you must be a non-smoker.

While Wellbutrin use for weight loss is promising, ALL studies show that it is more effective if it is complimented with a healthy diet and exercise. With that being said, you can’t pin all your weight loss hopes on Wellbutrin alone – you need to do your part too. As long as you eat healthy and exercise regularly, bupropion can help out with the rest of your weight woes.

Wellbutrin Uses, Dosage & Side Effects. (n.d.). Retrieved March 11, 2018, from https://www.drugs.com/wellbutrin.html

Why and How Wellbutrin May Be an Effective Treatment for ADHD

Can I Use Wellbutrin for ADHD?

Wellbrutin is an antidepressant that is commonly prescribed as an off-label treatment for ADHD. While stimulant medications are the first line of treatment, scientific research has shown that using Wellbutrin may help to improve ADHD symptoms, including impulsivity, hyperactivity, and inattention.

About Wellbutrin: Off-Label ADHD Treatment

Stimulant medications — methylphenidates and amphetamines — are the first-line ADHD treatment prescribed by the vast majority of clinicians. Why? Because they work for 70 to 80 percent of patients with attention deficit disorder (ADHD or ADD).

But what about those who have a less-than-optimal response to stimulant medications? What about the ADHD patients with other co-existing conditions, such as depression, anxiety, or other medical conditions? What about those who hesitate to try a stimulant? An alternative medication option considered and prescribed for a growing number of adults with ADHD is Wellbutrin, the trade name for the anti-depressant drug Bupropion.

Wellbutrin was first approved for use as an anti-depressant by the Federal Drug Administration (FDA) in 1985. Since then, it has been used to treat seasonal affective disorder (SAD) and help minimize nicotine cravings when stopping smoking. Although it is classified as an anti-depressant, Wellbutrin enhances actions that impact dopamine and norepinephrine in the brain, so today it is also commonly prescribed as an “off-label” treatment for ADHD.

Are “off-label” medications legal?

Prescribing “off-label” is legal and common. A medication can be prescribed “off-label” when research has shown that it might help with a condition (like ADHD), even though it is not currently approved by the FDA for that specific condition. In this case, Wellbutrin has been approved to treat depression, and scientific studies 1, 2, 3 have shown that it might help improve concentration, focus, and other symptoms of ADHD for patients aged 18 and older.

How Wellbutrin Works: Off-Label ADHD Treatment

Wellbutrin, like other medications used to treat ADHD, affects neurotransmitter function in the brain. Specifically, it blocks the reuptake (reabsorption) of dopamine and norepinephrine by the presynaptic neuron after those chemicals have been released from the nerve cell. Medications that act in this way are called NDRIs (Norepinephrine Dopamine Reuptake Inhibitors).

Reuptake is a normal way the body controls how long a nerve signal lasts. Blocking the reuptake increases the concentration of dopamine and norepinephrine active in the brain. When more of these neurotransmitters stay active, they are available to send messages to other nerves. In this case, more is better.

Why Use Wellbutrin for ADHD Symptoms?

If stimulants are the most effective treatment for ADHD, why would someone be prescribed Wellbutrin? There are several reasons:

  1. Not everyone taking stimulant medication experiences a significant reduction of his or her ADHD symptoms. In these cases, adding Wellbutrin, which enhances the action of dopamine and norepinephrine in the brain, might help.
  2. Patients taking stimulant medications sometimes experience negative side effects. The action of Wellbutrin is different than that of stimulant medications, so some patients may experience fewer negative side effects on Wellbutrin.
  3. The majority of ADHD patients also have at least one comorbid condition. Co-existing conditions, such as depression and anxiety, are more than common — they are the norm for patients with ADHD. Adding an antidepressant, such as Wellbutrin, can sometimes help in treating and minimizing these symptoms.
  4. An underlying medical or psychiatric condition may make the prescription of a stimulant medication less than ideal. For example, a heart condition, sleep disorders, tic disorder, a history of addiction, and some other psychiatric conditions such as mood disorders may preclude a patient from safely taking a stimulant medication.

Dose and Forms of Wellbutrin for ADHD Treatment

Wellbutrin comes in three forms:

  • Wellbutrin
  • Wellbutrin SR (sustained-release): Lasts 12 hours and is taken twice a day
  • Wellbutrin XL (extended release): Lasts 24 hours and is taken once a day

For ADHD, Wellbutrin is usually prescribed in the extended release (XL) form and can be taken with or without food. It is often safely combined with another ADHD medication. The starting dose for adults is typically 150mg, and that can be gradually increased up to 450 mg daily. It’s common for the dosages to be divided into morning and nighttime. The specific dose for an individual differs depending on the effectiveness of the medication.

According to the existing research, Wellbutrin hasn’t been shown to be safe and effective for use in people younger than 18 years old.

Common Side Effects of Wellbutrin

  • dizziness
  • low appetite
  • blurry vision
  • agitation, increased anxiety
  • difficulty sleeping
  • headache
  • dry mouth
  • nausea or vomiting
  • constipation
  • sweating
  • muscle twitching, restlessness

Important Information About Taking Wellbutrin for ADHD

  • It can take some time to realize the full benefit of Wellbutrin. In contrast to the quick onset of stimulant medication, it may take patients approximately 3 to 7 days to notice any benefits of Wellbutrin. It may also take several weeks for a prescriber and patient to find the most effective therapeutic dose. Once the dose has been adjusted, it can take an additional 4-6 weeks for a patient to experience the full benefit of Wellbutrin. While the dosage is being determined, signs that the medication is working are an improved mood, increased appetite, and better sleep.
  • Wellbutrin should not be discontinued without a physician’s assistance. Patients who want to stop taking Wellbutrin should discuss this with their physician. Patients may experience irritability when stopping Wellbutrin abruptly.
  • Wellbutrin is not considered safe to take during pregnancy or while breastfeeding.
    Patients who are pregnant or planning to become pregnant should discuss medications with their clinician.
  • Wellbutrin’s black box warning is important. The FDA puts a warning on certain prescription medications that may have serious or life-threatening risks. Wellbutrin has a black box warning about the possibility of suicidal thoughts or action in children, teens, and young adults. Wellbutrin hasn’t been shown to be safe and effective for use in people younger than 18 years old. There’s no FDA-approved dosage for children. Knowing this risk helps parents, caregivers, and partners watch for any changes in their loved one such as suicidal thoughts, behavior, or attempted suicide.

For all of these reasons, it is important for prescribers and patients to discuss the benefits versus the risks of Wellbutrin, to stay in close contact, and to schedule regular follow-up appointments while taking this medication.

Though Wellbutrin is not a first-line medication treatment for ADHD, it can be helpful in treating ADHD symptoms for some people. Patients interested in adding Wellbutrin as part of an ADHD treatment plan should discuss the options with their prescribing clinician.

Laurie Dupar, PMHNP, RN, PCC, is a member of the ADDitude ADHD Medical Review Panel.

1 Barrickman LL, Perry PJ, and Allen AJ. et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 34:649–657.
2 Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD . Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December 2003 San Juan, Puerto Rico.
3 Conners CK, Casat CD, and Gualtieri CT. et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 34:1314–1321.


Updated on November 12, 2019


I’ve been suffering from depression and anxiety for the past few years. Although I’ve made tremendous progress mentally due to consulting a therapist, I still feel unmotivated to do things on a daily basis, and in general just feeling down having little energy, so I decided to try medication. The psychiatrist first prescribed Aventyl (Nortriptyline), and after taking it for 3 days, I felt much worse than before… just not seeing the point in doing anything and whatever small motivation that I previously had was gone. So I stopped it and went back to the doctor. This time, he prescribed Wellbutrin (Bupropion).
I was taking 100mg Bupropion SR (generic) for about 2 weeks. I felt somewhat better the first 2 days but then felt really tired and unmotivated again. One day, after taking it for a little less than two weeks, I felt slightly better again. I went back to see the doctor and he upped the dose to 150mg XL instead of SR. Today is my third day on the 150mg XL. I was feeling really great on the first day, I felt like I had alot of energy and could have many things done. Second day, I was energetic and in a positive mood at first, but then it faded maybe around 4 hours later and I went back to feeling tired and unmotivated. Today, I felt really emotional and felt like crying when I was in public, I feel unmotivated and have no energy at all, I just want to be alone with minimal social interaction and am not happy with my life at all.
I will soon complete the third week on this drug and still no positive effects. Does anyone have experience with Wellbutrin? What are your thoughts?


  • Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry. 1983 44(sec 2). 67–73.
  • Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000
  • Wellbutrin (bupropion) tablets, Wellbutrin SR (bupropion), and Wellbutrin XL (bupropion). Physician’s Desk Reference. Montvale, NJ: Thomson PDR. 2005 1655–1659. 1659,–1663. 1663–1668.
  • Dunner DL, Zisook S, and Billow AA. et al. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry. 1998 59:366–373.
  • Johnston JA, Fiedler-Kelly J, and Glover ED. et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation. Nicotine Tob Res. 2001 3:131–140.
  • Depression Patient Study. New Hanover, NJ: NOP World Health. 2002.
  • Ferris RM, Cooper BR, and Maxwell RA. Studies of bupropion’s mechanism of antidepressant activity. J Clin Psychiatry. 1983 44(sec 2). 74–78.
  • Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill. 2001 447–483.
  • Ascher JA, Cole JO, and Colin J-N. et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995 56:395–401.
  • Stahl SM, Pradko JF, Haight BR. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159–166.
  • Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001;155:52–57.
  • Stahl SM. Essential Psychopharmacology, First Edition. New York, NY: Cambridge University Press. 1996
  • Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol. 1996;16(3 suppl 2):1S–9S.
  • Yatin SM, Miller GM, and Norton C. et al. Dopamine transporter-dependent induction of c-fos in HEK cells. Synapse. 2002 45:52–65.
  • Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther. 1980;215:127–134.
  • Learned-Coughlin SM, Bergstrom M, and Savitcheva I. et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003 54:800–805.
  • Meyer JH, Goulding VS, and Wilson AA. et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002 163:102–105.
  • Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results. Eur Neuropsychopharmacol. 2003 13suppl 4. S210. Abstract No P.1.085.
  • Fabre LF, Brodie HK, and Garver D. et al. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry. 1983 44(sec 2). 88–94.
  • Lineberry CG, Johnston JA, and Raymond RN. et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry. 1990 51:194–199.
  • Coleman CC, Cunningham LA, and Foster VJ. et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained-release and sertraline treatment. Ann Clin Psychiatry. 1999 11:205–215.
  • Croft H, Settle E, and Houser T. et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999 21:643–658.
  • Feighner JP, Gardner EA, and Johnston JA. et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991 52:329–335.
  • Kavoussi RJ, Segraves RT, and Hughes AR. et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry. 1997 58:532–537.
  • Coleman CC, King BR, and Bolden-Watson C. et al. A placebo-controlled comparison on sexual functioning of bupropion SR and fluoxetine. Clin Ther. 2001 23:1040–1058.
  • Weihs KL, Settle EC, and Batey SR. et al. Bupropion sustained-release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000 61:196–202.
  • Mendels J, Amin MM, and Chouinard G. et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry. 1983 44(sec 2). 118–120.
  • Branconnier RJ, Cole JO, and Ghazvinian S. et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry. 1983 44(sec 2). 130–133.
  • Masco HL, Kiev A, and Holloman LC. et al. Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr Ther Res. 1994 55:851–863.
  • Feighner J, Hendrickson G, and Miller L. et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol. 1986 6:27–32.
  • Weisler RH, Johnston JA, and Lineberry CG. et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994 14:170–179.
  • Thase ME, Haight BR, and Richard N. et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. In press.
  • Rush AJ, Trivedi MH, and Carmody TJ. et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology. 2002 25:131–138.
  • Weihs L, Houser T, and Batey S. et al. Continuation phase treatment with bupropion SR decreases risk for relapse of depression. Biol Psychiatry. 2002 51:753–761.
  • Bodkin JA, Lasser RA, and Wines JD Jr. et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997 58:137–145.
  • Spier SA. Use of bupropion with SSRIs and venlafaxine. Depress Anxiety. 1998;7:73–75.
  • DeBattista C, Solvason HB, and Poirier J. et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol. 2003 23:27–30.
  • Lam RW, Hossie H, and Solomons K. et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004 65:337–340.
  • Ferguson J, Cunningham L, and Meridith C. et al. Bupropion in tricyclic nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry. 1994 6:153–169.
  • Stern WC, Harto-Truax N, and Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry. 1983 44(sec 2). 148–152.
  • Fava M, Papakostas GI, and Petersen T. et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003 15:17–22.
  • Fava M, Rush AJ, and Trivedi MH. et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003 26:457–494.
  • Dilsaver SC, Qamar AB, Del Medico VJ. The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry. 1992;53:252–255.
  • Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and 5 years of postmarketing experience. Int J Clin Pract. 2003;57:224–230.
  • Hurt RD, Sachs DP, and Glover ED. et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997 227:1195–1202.
  • Jorenby DE, Leischow SJ, and Nides MA. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 340:685–691.
  • Tonstad S, Farsang C, and Klaene G. et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicenter, randomized study. Eur Heart J. 2003 24:946–955.
  • Tashkin DP, Kanner RK, and Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet. 2001 357:1571–1575.
  • Hays JT, Hurt RD, and Rigotti NA. et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med. 2000 135:423–433.
  • Shopsin B. Bupropion’s prophylactic efficacy in bipolar affective illness. J Clin Psychiatry. 1983 44(sec 2). 163–169.
  • Wright G, Galloway L, and Kim J. et al. Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects. J Clin Psychiatry. 1985 46:22–25.
  • Sachs GS, Lafer B, and Stoll AL. et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994 55:391–393.
  • Guille C, Demopulos C, and Sachs G. Bupropion vs desipramine in the treatment of bipolar depression . Presented at the 151st annual meeting of the American Psychiatric Association; May 30–June 4, 1998; Toronto, Ontario, Canada.
  • Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 1990;147:1018–1020.
  • Barrickman LL, Perry PJ, and Allen AJ. et al. Bupropion versus methylphenidate in the treatment of ADHD. J Am Acad Child Adolesc Psychiatry. 1995 35:649–657.
  • Conners CK, Casat CD, and Gualtieri CT. et al. Bupropion in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 34:1314–1321.
  • Wilens TE, Spencer TJ, and Biederman J. et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001 158:282–288.
  • Gardner EA. Effects of bupropion on weight in patients intolerant to previous antidepressants. Curr Ther Res. 1985;35:188–199.
  • Gadde KM, Parker CB, and Maner LG. et al. Bupropion for weight loss: investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 9:544–551.
  • Jain AK, Kaplan RA, and Gadde KM. et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002 10:1049–1056.
  • Anderson JW, Greenway FL, and Fujioka K. et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002 10:633–641.
  • Anderson JW, Greenway FL. The effect of bupropion sustained release on weight loss in obese adolescents . Presented at the 157th annual meeting of the American Psychiatric Association; May 1–6, 2004; New York, NY.
  • Settle EC, Stahl SM, and Batey SR. et al. Safety of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999 21:454–463.
  • Settle EC. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998 59suppl 4. 32–36.
  • Thase ME, Haight B, and Hunt T. et al. Bupropion SR does not affect blood pressure of hypertensive patients . Presented at the 156th annual meeting of the American Psychiatric Association; May 17–22, 2003; San Francisco, Calif.
  • Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry. 1998 59suppl 18. 23–29.
  • Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry. 2002 63suppl 5. 13–16.
  • Clayton AH, Pradko JF, and Croft HA. et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002 63:357–366.
  • Clayton AH, Warnock JK, and Kornstein SG. et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor–induced sexual dysfunction. J Clin Psychiatry. 2004 65:62–67.
  • Clayton AH, McGarvey EL, and Abouesh AI. et al. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry. 2001 62:185–190.
  • Croft H, Houser TL, and Jamerson B. et al. Effect on body weight of bupropion SR in patients with major depression treated for 52 weeks. Clin Ther. 2002 24:662–672.

What is bupropion, or Wellbutrin?

Wellbutrin may not be suitable for people with:

  • liver or kidney problems
  • bipolar disorder
  • diabetes
  • high blood pressure

Those who regularly drink large amounts of alcohol may not be able to take it.

These people should not use this drug without first discussing it with their doctor.

Monoamine oxidase inhibitors

Monoamine oxidase inhibitors (MAOIs) are also used to treat depression. Anyone who is taking a MAOI should avoid Wellbutrin.

If taken together, side effects may include confusion, restlessness, stomach discomfort or pain, high body temperature, dangerously high blood pressure, leading to headaches, dizziness, and blurred vision, and an increased risk of convulsions.

MAOIs include:

  • Isocarboxazid (Marplan)
  • Phenelzine (Nardil)
  • Selegiline (Emsam)
  • Tranylcypromine (Parnate)

Wellbutrin should not be taken within 2 weeks of stopping MAOIs. Similarly, individuals should not start taking MAOIs within 2 weeks of stopping Wellbutrin.

When used to help people stop smoking, bupropion is sold as Zyban or Chantix. The Food and Drug Administration (FDA) warns that people who are taking one of these drugs to stop smoking must not take the same drug under another name to treat depression.

This will increase the dose of the same ingredients, and it may raise the risk of seizures.

Other drug interactions

Ritonavir or efavirenz are used to treat HIV infection. These can reduce the effects of Wellbutrin.

People with liver problems should discuss with their doctor whether or not Wellbutrin is suitable, before taking it.


A severe allergic reaction known as anaphylaxis can occur if a person has an allergy to any of the ingredients in Wellbutrin.

If any of the following symptoms occur, medical assistance should be sought immediately: a skin rash, itching, trouble breathing, chest pain, or swelling of the face, tongue, or throat.

Skin reactions

Anyone experiencing any of the following reactions should seek medical advice:

  • red lesions
  • severe acne or a skin rash
  • sores or ulcers on the skin
  • fever or chills
  • blistering or peeling
  • loosening of the skin

Other considerations

Alcohol: This should be avoided or at least severely limited when using Wellbutrin, as it has been linked to neuropsychotic side effects in a few cases.

Pregnancy and breastfeeding: Mouse studies have not shown that Wellbutrin is likely to harm a pregnancy or the developing fetus. However, since drugs do not alway affect humans and animals in the same way, this drug should only be used in pregnancy and breast feeding if it cannot be avoided.

Age: It has not been approved for use under the age of 18 years.

Bipolar disorder: A major depressive episode can develop into the first signs of bipolar disorder. A doctor should monitor the patient for signs of this. Wellbutrin is not approved for use in bipolar disorder.

Driving and use of machinery: Dizziness, tiredness, blurred vision, and a false sense of wellbeing can occur when using this drug. Because of this, using heavy machinery or driving should be considered with caution.

Overdose: In rare cases, an overdose has led to seizures. Anyone who may have taken an overdose should go to the hospital.

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *